FOCUS on Drug Failures. On December 22nd AstraZeneca reported on the LATIFY Phase III trial of ATR inhibitor ceralasertib (AZD6738) in combination with Imfinzi (Durvalumab), which did not meet the primary endpoint of overall survival versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer. “The goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumors stopped responding to available therapies by combining ATR inhibition with immunotherapy.”
Focus Biomolecules can supply ceralasertib for research applications. For more information contact us.
